A Randomized, Double-Blind Study of Fenofibric Acid Plus Rosuvastatin Compared With Rosuvastatin Alone in Stage 3 Chronic Kidney Disease.

CONCLUSIONS: The data suggest that, after 16 weeks of therapy, FA + R has an acceptable safety profile and improved TG and HDL-C efficacy versus R. FA + R combination therapy may thus further improve lipid parameters in patients with stage 3 CKD and mixed dyslipidemia. ClinicalTrials.gov identifier: NCT00680017. PMID: 23891363 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23891363?dopt=Abstract

Source: Clinical Therapeutics - July 25, 2013 Category: Drugs & Pharmacology Authors: Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, Lele A, Stolzenbach JC Tags: Clin Ther Source Type: research